Trump Drug Price Plan Slashes Costs, Says CMS Chief Oz
Published by YuToday Staff
0 views · 3 hours ago · 5:04 read · September 2, 2026
President Donald Trump has secured expanded drug discount deals with 26 pharmaceutical companies, a move that could save Americans over $600 billion on prescription medications. CMS Administrator Dr. Mehmet Oz discussed the agreements on FOX Business, highlighting their potential to curb rising healthcare costs. The initiative targets Medicare and broader prescription drug expenses, aiming to align U.S. prices more closely with those in Europe and Asia.
Key takeaways
- President Trump’s drug discount deals with 26 manufacturers could save Americans over $600 billion on prescription medications.
- The plan targets Medicare and aims to align U.S. drug prices more closely with those in Europe and Asia.
- CMS Administrator Dr. Mehmet Oz outlined the policy’s potential to reduce out-of-pocket expenses for seniors and low-income families.
- Industry and lawmaker reactions are divided, with debates over innovation, affordability, and the role of government in pricing.
How the Trump Drug Price Plan Works
The Trump administration’s drug pricing strategy hinges on negotiated discounts with major pharmaceutical manufacturers. By leveraging Medicare’s purchasing power, the plan aims to cap prices for widely used medications, including those for chronic conditions like diabetes and heart disease. The agreements cover 26 drugmakers, though specific drugs and discount percentages remain unconfirmed. The initiative builds on earlier efforts to address skyrocketing prescription costs, which have burdened American households and strained federal healthcare budgets. Critics argue the plan may not go far enough, while supporters praise its potential to make essential drugs more affordable. The White House has framed the policy as a step toward aligning U.S. drug prices with global standards, where costs are often lower.
What CMS Chief Dr. Mehmet Oz Says About the Policy
Dr. Mehmet Oz, Administrator of the Centers for Medicare & Medicaid Services (CMS), emphasized the policy’s potential to deliver immediate financial relief to millions of Americans. Speaking on FOX Business, Oz noted that the discounts could reduce out-of-pocket expenses for seniors and low-income families, particularly for high-cost medications. He also highlighted the broader economic impact, suggesting that lower drug prices could ease financial strain on households and reduce Medicare spending. While Oz did not disclose specific savings figures per drug, he reiterated the administration’s commitment to transparency and accountability in pharmaceutical pricing. The CMS chief also addressed concerns about industry pushback, stating that negotiations were conducted in good faith to balance affordability with innovation.
Impact on Medicare and Healthcare Costs
The drug discount deals are expected to have a significant impact on Medicare, which spends billions annually on prescription medications. By securing lower prices, the Trump administration aims to reduce Medicare’s financial burden while improving access to critical drugs for beneficiaries. The policy could also set a precedent for private insurers, encouraging them to negotiate similar discounts. However, the long-term effects on drug innovation and manufacturer profits remain debated. Some analysts warn that reduced revenue for pharmaceutical companies could slow research and development, while others argue that the current pricing system is unsustainable. The administration has not provided details on how savings will be reinvested, leaving questions about the plan’s broader healthcare implications unanswered.
Reaction from Industry and Lawmakers
The pharmaceutical industry has yet to issue a unified response, though individual companies have expressed varying degrees of support for the initiative. Some manufacturers have signaled willingness to collaborate, while others have raised concerns about profit margins and the potential for government overreach. On Capitol Hill, reactions are similarly divided. Republican lawmakers have largely praised the plan as a market-driven solution to high drug prices, while Democrats have called for more aggressive reforms, including Medicare price negotiations for all drugs. The policy’s reception among healthcare advocates is mixed, with some praising its potential to lower costs and others criticizing its reliance on voluntary agreements rather than binding regulations.
Global Comparisons: How U.S. Drug Prices Stack Up
The Trump administration’s push to lower drug prices reflects a broader trend of aligning U.S. costs with those in Europe and Asia, where prescription medications are often significantly cheaper. In countries like Canada and Germany, price controls and bulk purchasing enable lower costs, though critics argue that such systems can lead to drug shortages or reduced innovation. The U.S., by contrast, has historically allowed pharmaceutical companies to set prices based on market demand, resulting in some of the highest drug costs in the world. The new policy aims to bridge this gap, though the extent of its success will depend on the willingness of manufacturers to participate and the durability of the agreements. Comparisons with other nations’ pricing models remain a contentious topic, with no clear consensus on the best approach.
What’s Next for the Drug Price Plan?
The next phase of the Trump administration’s drug pricing strategy will likely focus on implementation and enforcement. CMS is expected to release further details on how discounts will be applied, including which drugs are covered and how savings will be passed to consumers. Lawmakers may also introduce legislation to codify the agreements, ensuring their longevity beyond the current administration. Meanwhile, pharmaceutical companies will need to adapt to the new pricing landscape, potentially adjusting their research priorities or expanding into lower-cost markets. The policy’s success will hinge on its ability to deliver tangible savings without stifling innovation or limiting access to new treatments. Public feedback and industry responses will play a critical role in shaping the plan’s future.
What happens next
The Trump administration’s drug price plan is poised to enter a critical implementation phase, with CMS expected to release further details in the coming weeks. Lawmakers may introduce legislation to solidify the agreements, while pharmaceutical companies will need to adapt to the new pricing landscape. Public feedback and industry responses will shape the policy’s future, determining whether it delivers on its promise of significant savings without compromising innovation or access to new treatments.
People also ask
Which drugs are included in the Trump administration’s discount deals?
The specific drugs covered by the agreements have not been disclosed. The Trump administration has not provided a detailed list of medications included in the discounts.
How will the drug price plan affect Medicare spending?
The plan is designed to reduce Medicare’s financial burden by lowering prescription drug costs. Exact savings figures for Medicare are unconfirmed, but the administration estimates significant reductions in overall spending.
Will the drug discounts apply to all Americans or just Medicare beneficiaries?
The policy primarily targets Medicare, but its impact could extend to private insurers and other healthcare programs. The administration has not specified whether discounts will be available to all Americans.
What are the potential drawbacks of the drug price plan?
Critics argue that lower drug prices could reduce revenue for pharmaceutical companies, potentially slowing research and development. Others warn that the plan may not go far enough to address systemic issues in drug pricing.